{
    "nctId": "NCT02819921",
    "briefTitle": "Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen",
    "officialTitle": "Desvenlafaxine for the Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen: a Randomized, Double-blind, Placebo-controlled Study",
    "overallStatus": "TERMINATED",
    "conditions": "Hot Flashes, Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 59,
    "primaryOutcomeMeasure": "Reduction rate of hot flashes symptom score",
    "eligibilityCriteria": "Inclusion Criteria:\n\ni. Women age 18 years and older with localized breast cancer. Histologic documentation of atypical ductal hyperplasia, ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), or invasive adenocarcinoma of the breast stages I-III A.\n\nii. Current daily tamoxifen use (\u2265 6 days/week). Any planned surgery, adjuvant chemotherapy or radiation must have been completed.\n\niii. History of bothersome hot flushes: \u2265 14 hot flushes/week (average \u2265 2 hot flushes/day), sufficiently severe that intervention is desired. Participants must have had bothersome hot flushes for at least one month prior to enrollment.\n\nExclusion Criteria:\n\ni. Women who is pregnant or breast feeding, or who has a history of seizure disorder or hepatic or renal insufficiency ii. Concurrent systemic hormone replacement therapy (estrogen, progestational agents, androgens) or use of corticosteroids iii. Concurrent use of other antidepressants, anxiolytics and antipsychotics, gabapentin, pregabalin and clonidine for treatment of hot flushes or depression.\n\niv. Presense or past history of severe psychiatric symptoms such as hallucinations and delusions, manic episodes, or high suicide risk.",
    "sex": "FEMALE",
    "minimumAge": "19 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}